Related Experiment Video
Updated: Aug 5, 2026
05:58
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
[Cardiological use of mononitrates]
Klinicheskaia Meditsina
|June 2, 2000
Summary
Isosorbide-5-mononitrate (I-5-M), marketed as Monochinque retard, effectively lowers blood pressure and reduces angina attacks. This study shows its benefits in improving heart function and alleviating symptoms in coronary heart disease patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease (CHD) presents with anginal pain and myocardial ischemia.
- Heart failure (HF) significantly impacts patients' quality of life, with functional classes II-IV indicating moderate to severe limitations.
Purpose of the Study:
- To evaluate the antihypertensive and anti-ischemic effects of isosorbide-5-mononitrate (I-5-M).
- To assess the impact of Monochinque retard (50 mg) on clinical manifestations and hemodynamic parameters in patients with CHD and heart failure.
Main Methods:
- Utilized Holter monitoring to assess myocardial ischemia.
- Evaluated central hemodynamic parameters, including left ventricular systolic and diastolic functions.
- Clinical assessment of anginal attacks and heart failure functional classes.
Main Results:
- Monochinque retard (50 mg) demonstrated significant reduction in anginal attacks and alleviation of myocardial ischemia.
- Observed positive changes in left ventricular systolic and diastolic functions.
- Improved clinical manifestations in both symptomatic and asymptomatic coronary heart disease patients, including alleviation of heart failure functional classes II-IV.
Conclusions:
- Isosorbide-5-mononitrate (I-5-M) exhibits marked antihypertensive and anti-ischemic properties.
- Monochinque retard (50 mg) is effective in managing coronary heart disease and heart failure symptoms.
- The drug positively influences central hemodynamics and improves overall patient outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...